Mortality in Patients with Biopsy-proven Giant Cell Arteritis: A South Australian Population-based Study

被引:47
|
作者
Ninan, Jem [1 ]
Anh-Minh Nguyen [3 ]
Cole, Antonia [1 ]
Rischmueller, Maureen [1 ]
Dodd, Thomas [4 ]
Roberts-Thomson, Peter [5 ]
Hill, Catherine L. [1 ,2 ]
机构
[1] Queen Elizabeth Hosp, Rheumatol Unit, Woodville, SA 5011, Australia
[2] Univ Adelaide, Hlth Observ, Woodville, SA, Australia
[3] Dept Hlth, Hlth Stat Unit, Woodville, SA, Australia
[4] SA Pathol, Dept Tissue Pathol, Woodville, SA, Australia
[5] Flinders Med Ctr, Dept Allergy Immunol & Arthrit, Woodville, SA, Australia
关键词
MORTALITY RATE; GIANT CELL ARTERITIS; BIOPSY-PROVEN; TEMPORAL ARTERITIS; POLYMYALGIA-RHEUMATICA; SURVIVAL;
D O I
10.3899/jrheum.101254
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To compare mortality rates and cause of death in patients with biopsy-proven giant cell arteritis (GCA) with those in the general population. Methods. Patients with biopsy-proven GCA were identified from pathology reports of temporal artery biopsies in South Australia, from January 1, 1992, to December 31, 2006. All patients with biopsy-proven GCA were linked to the South Australian Births, Death and Marriage Registry to identify deaths until December 31, 2006. Standardized mortality ratios and relative survival (ratio of observed survival in GCA group to expected survival of general South Australian population, matched by age, sex, and calendar time) were calculated. The cause of death recorded on the death certificate was also documented. Results. There were 225 cases of biopsy-proven GCA (163 women and 62 men). The mean age at diagnosis of GCA was 78.2 years. The mean followup period was 66.2 months (SD 47.1 mo). During the followup period, there were 71 deaths in the GCA group (50 women, 21 men). The standardized mortality ratio was 0.99 (95% CI 0.77-1.25). The relative survival for different followup periods demonstrates that patients with GCA experienced similar mortality to the general population (age-matched and sex-matched). Death from cardiovascular causes (45%) was the most common, followed by infection (17%) and cancer (17%). Infection was a significantly more common cause of death in the first year (chi-squared, p = 0.0002). Conclusion. Our population-based cohort study did not demonstrate any increased mortality risk for patients diagnosed with biopsy-proven GCA. The risk of death from infection early in the disease may be increased. (First Release Aug 15 2011; J Rheumatol 2011;38:2215-17; doi:10.3899/jrheum.101254)
引用
收藏
页码:2215 / 2217
页数:3
相关论文
共 50 条
  • [21] Incidence And Seasonal Variation Of Biopsy-Proven Giant Cell Arteritis - Revisited: A 20-Year Population-Based Study From Sweden
    Stamatis, Pavlos
    Turesson, Carl
    Nilsson, Jan-Ake
    Mohammad, Aladdin
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [22] PREVALENCE OF BIOPSY-PROVEN GIANT CELL ARTERITIS IN SOUTHERN SWEDEN
    Stamatis, Pavlos
    Turkiewicz, Aleksandra
    Englund, Martin
    Turesson, Carl
    Mohammad, Aladdin
    RHEUMATOLOGY, 2019, 58 : 72 - 72
  • [23] Relapse Characteristics and Glucocorticoid Use in Patients with Biopsy-Proven Giant Cell Arteritis
    Koster, Matthew J.
    Labarca, Cristian
    Crowson, Cynthia S.
    Makol, Ashima
    Ytterberg, Steven R.
    Matteson, Eric L.
    Warrington, Kenneth J.
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [24] EPIDEMIOLOGY OF BIOPSY-PROVEN GIANT-CELL ARTERITIS (GCA)
    NORDBORG, E
    BENGTSSON, BA
    JOURNAL OF INTERNAL MEDICINE, 1990, 227 (04) : 233 - 236
  • [25] FREQUENCY AND PREDICTIVE VARIABLES OF RELAPSES IN PATIENTS WITH BIOPSY-PROVEN GIANT CELL ARTERITIS
    Restuccia, G.
    Boiardi, L.
    Muratore, F.
    Cavazza, A.
    Cimino, L.
    Aldigeri, R.
    Macchioni, P.
    Catanoso, M. G.
    Pipitone, N.
    Salvarani, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 160 - 160
  • [26] Biopsy-proven giant-cell arteritis and visual loss
    Pahor, Dusica
    Kavalar, Rajko
    Pahor, Artur
    SPEKTRUM DER AUGENHEILKUNDE, 2016, 30 (4-5) : 169 - 174
  • [27] The frequency and pattern of diplopia in biopsy-proven giant cell arteritis
    Cornblath, WT
    Turner, TD
    NEUROLOGY, 2001, 56 (08) : A14 - A14
  • [28] NO ASSOCIATION BETWEEN FCGR3B, TLR4 AND SOUTH AUSTRALIAN BIOPSY-PROVEN GIANT CELL ARTERITIS PATIENTS
    Dunstan, E.
    Lester, S.
    Hewitt, A.
    Rischmueller, M.
    Hill, C.
    INTERNAL MEDICINE JOURNAL, 2013, 43 : 21 - 22
  • [29] COMPARISON OF BIOPSY PROVEN GIANT CELL ARTERITIS IN NORTH AMERICA AND SOUTHERN EUROPE: A POPULATION-BASED STUDY
    Muratore, Francesco
    Crowson, Cynthia S.
    Boiardi, Luigi
    Koster, Matthew J.
    Restuccia, Giovanna
    Kermani, Tanaz A.
    Matteson, Eric L.
    Salvarani, Carlo
    Warrington, Kenneth J.
    RHEUMATOLOGY, 2017, 56 : 52 - 52
  • [30] COMPARISON OF BIOPSY PROVEN GIANT CELL ARTERITIS IN NORTH AMERICA AND SOUTHERN EUROPE: A POPULATION-BASED STUDY
    Muratore, F.
    Crowson, C. S.
    Boiardi, L.
    Koster, M. J.
    Restuccia, G.
    Kermani, T. A.
    Matteson, E. L.
    Salvarani, C.
    Warrington, K. J.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 609 - 610